Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT03933735
A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma
- NCT03933735 ↗
- Active, not recruiting
- AbbVie
- Focused
We haven't built an HCP commentary report on NCT03933735 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03933735 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- TNB-383B
- Arms
- Arm A: Dose Escalation · Experimental
- Arm B: Dose Expansion Dose A · Experimental
- Arm B: Dose Expansion Dose B · Experimental
- Arm E: Monotherapy Once Every 4 Weeks (Q4W) · Experimental
- Arm F: Monotherapy Dose C · Experimental
- Enrollment
- 220
- Primary outcomes
- Number of Participants with Dose-limiting toxicities (DLT)
- Number of Participants with Adverse Events (AEs) and/or Serious Adverse Events (SAEs)
- Maximum Observed Plasma Concentration of TNB-383B (Cmax)
- Time to Cmax of TNB-383B (Tmax)
- Area Under the Concentration Versus Time Curve from Time Zero to the Last Measurable Concentration (AUClast)
- Clearance (CL) of TNB-383B
- Terminal Phase Elimination Rate Constant (Beta) of TNB-383B
- Terminal Half-Life (t1/2) of TNB-383B
- Number of Participants with of Anti-drug Antibody (ADA)
- Sponsor
- AbbVie
- Start
- Jun 24, 2019
- Primary completion
- May 2026 (estimated)
- Results posted
- No
- Registry record
- NCT03933735 · updated Feb 6, 2026
Publications
linked from the registry- D'Souza A, Shah N, Rodriguez C, Voorhees PM, Weisel K, Bueno OF, Pothacamury RK, Freise KJ, Yue S, Ross JA, Polepally AR, Talati C, Lee S, Jin Z, Buelow B, Vij R, Kumar S. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen x CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2022 Nov 1;40(31):3576-3586. doi: 10.1200/JCO.22.01504. Epub 2022 Aug 27. PubMed 36029527